Argenx SE (ARGX) has been showing promising progress, hitting an all-time high with the stock value at $803.95 and receiving multiple
Buy ratings from leading firms like Evercore ISI, TD Cowen, Deutsche Bank, and Wedbush. This confidence comes from their recent
success with myasthenia gravis drug
Vyvgart's late-stage trial, enabling the firm to expand to broader populations. Rapid advancements, such as the FDA's approval of efgartigimod alfa for CIDP treatment and positive outcomes from ADAPT SERON, further push Argenx's stock performance. It also inked a $1.5 billion deal with Unnatural Products to explore 'undruggable' targets. Besides, Argenx's medical recognition extends to prominent strategic partnerships, including Fujifilm Biotechnologies expanding their collaboration globally and with US production. Moreover, they amplified myasthenia gravis awareness associating with iconic tennis player
Monica Seles at the U.S. Open. Despite a setback involving the FDA's regulatory action consideration over 'severe worsening' of disease, the company has taken robust strides with record growth and strategic advancements in Q2 and Q1 of 2025, charting a steady financial course.
argenx News Analytics from Wed, 19 Feb 2025 08:00:00 GMT to Sat, 18 Oct 2025 04:22:47 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
